Introduction: The glucagon-like peptide-1 receptor analogue (GLP-1RA) semaglutide is associated with improvements in glycaemia and cardiovascular risk factors in clinical trials. The aim of this study was to examine the real-world impact of semaglutide administered by injection in people with type 2 diabetes (T2D) across three secondary care sites in Wales. Methods: A retrospective evaluation of 189 patients with T2D initiated on semaglutide between January 2019 and June 2020 with at least one follow-up visit was undertaken. Results: At baseline, participants had a mean age of 61.1 years, mean glycated haemoglobin (HbA1c) of 77.8 mmol/mol (9.3%) and mean body weight of 101.8 kg. At 6 and 12 months of follow-up, mean HbA1c reductions of 13.3 mmol/mol (1.2%) and 16.4 mmol/mol (1.5%), respectively, were observed, and mean weight loss at 6 months was 3.0 kg (all p \ 0.001). At 12 months, there were significant reductions in total cholesterol (0.5 mmol/L) and alanine transaminase (4.8 IU/L). Patients naïve to GLP-1RAs or with higher baseline HbA1c at baseline had greater glycaemic reductions, although clinically significant HbA1c reductions were also observed in those who switched from other GLP-1RAs, whose body mass index was \ 35.0 and [ 35.0 kg/m 2 or who had lower baseline HbA1c. Semaglutide was generally well tolerated, although adverse-effects limited use in 18 patients (9.5%). Conclusion: Semaglutide provided clinically and statistically significant reductions in HbA1c, body weight, lipids and liver enzymes.

Background and aimsWe examined HbA1c and cardiovascular risk factors with a median follow-up of 44 months therapy with dapagliflozin. MethodsWe undertook a clinical practice evaluation of 101 patients attending our clinic. ResultsDapagliflozin resulted in a significant reduction in HbA1c 82.6 ±15.7 v 68.7 ±17.8 mmol/mol. ConclusionDapagliflozin maintains glycaemic control along with sustained improvements in weight and no decline in renal function.1. Dapagliflozin provides effective glycaemic control over a median of 44 months without deterioration in renal function.2. Weight loss was maintained with therapy during the treatment period.3. This supports maintained benefits associated with dapagliflozin during follow-up in routine clinical practice.